Marinus Pharmaceuticals Inc.
This article was originally published in Start Up
Executive Summary
Marinus Pharmaceuticals was founded to take ganaxolone, a problematic compound for which tantalizing human efficacy data already exists and reformulate it to overcome the pharmacokinetic and cost problems holding it back. In just two years since in-licensing it, Marinus has succeeded in reformulating the drug and putting it back into clinical testing for two epilepsy indications with hopes of building a multi-indication franchise around it.